Picture
"Chronic myelogenous leukemia (CML) is a disease characterized by the expression of BCR-ABL, an oncogenic tyrosine kinase that induces bone marrow stem cell proliferation. Untreated, there is progression from a relatively benign chronic phase, lasting 3 to 5 years, to a rapidly fatal acute leukemia (blast crisis). Impressive therapeutic advances in the management of CML have occurred in the past two decades, starting with the introduction of the tyrosine kinase inhibitor (TKI) imatinib, which dramatically improved survival in a large proportion of patients, and then introduction of second and third generation TKIs namely nilotinib, dasatinib, bosutinib and ponatinib for patients with imatinib resistance or intolerance"
Extract of Chronic Myeloid Leukemia - Clinical Practice Guideline
July 2020, Alberta Health Service
​SITES

CML  by Mayo Clinic
CML  by Cancer.net


See also   Precision medicine in chronic myeloid leukemia
See also   Philadelphia chromosome 
See also    BCR-ABL Transcripts 
See also    Sokal, Hasford, EUTOS  and  ACE-27 scores